8-K: MIRA Pharmaceuticals Announces Enrollment of First Subjects in Phase 1 Clinical Trial for Ketamir-2

MIRA Pharmaceuticals has initiated its Phase 1 clinical trial for Ketamir-2, a novel oral ketamine analog targeting neuropathic pain.

Summary

• MIRA Pharmaceuticals has commenced its Phase 1 clinical trial for Ketamir-2, an oral ketamine analog intended for neuropathic pain treatment.
• The trial is taking place at Hadassah Medical Center in Jerusalem, Israel.
• The study is a randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability, and pharmacokinetics of Ketamir-2 in healthy adult volunteers.
• A total of 56 subjects are expected to participate in the study, divided into Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts.
• Preclinical data showed Ketamir-2 had better efficacy in neuropathic pain models compared to pregabalin and gabapentin.
• Ketamir-2 also demonstrated a favorable safety profile, high oral bioavailability, and no interaction with P-glycoprotein (P-gp).
• The company expects to complete the Phase 1 study by the fourth quarter of 2025.
• A Phase 2a clinical trial in diabetic neuropathic pain is planned to start by year-end 2025.
• First human efficacy data are expected in the first half of 2026.

Sentiment

Score: 7

Explanation: The announcement is positive as it indicates progress in the clinical development of Ketamir-2. The preclinical data is promising, and the company is on track with its timeline. However, the success of the clinical trial is not guaranteed, so the sentiment is cautiously optimistic.

Positives

• The initiation of the Phase 1 clinical trial for Ketamir-2 is a significant milestone for MIRA Pharmaceuticals.
• Preclinical data suggests Ketamir-2 may be more effective than existing treatments for neuropathic pain.
• Ketamir-2 has a favorable safety profile, high oral bioavailability, and no interaction with P-glycoprotein (P-gp).
• The company is progressing towards Phase 2a clinical trials by the end of 2025.

Risks

• The success of the Phase 1 trial is not guaranteed, and the drug may not prove to be safe or effective in humans.
• The Phase 2a clinical trial may be delayed or may not produce positive results.
• The company may face regulatory hurdles in obtaining approval for Ketamir-2.

Future Outlook

MIRA Pharmaceuticals anticipates completing the Phase 1 study by the fourth quarter of 2025 and initiating a Phase 2a clinical trial in diabetic neuropathic pain by year-end. First human efficacy data are expected in the first half of 2026.

Management Comments

• MIRA Pharmaceuticals announced that the first subjects have been enrolled in its Phase 1 clinical trial with Ketamir-2.

Industry Context

The development of novel pain treatments is a significant area of focus in the pharmaceutical industry, given the limitations and side effects associated with existing therapies. MIRA's Ketamir-2, with its potential for improved efficacy and safety, could address a substantial unmet need in the treatment of neuropathic pain.

Comparison to Industry Standards

• Ketamir-2 is being compared to pregabalin (Lyrica) and gabapentin (Neurontin), which are established treatments for neuropathic pain.
• The claim of superior efficacy in preclinical models suggests a potential advantage over these existing drugs.
• Other companies developing pain treatments include Vertex Pharmaceuticals (VX-548) and Biohaven Pharmaceutical (Troriluzole), each with different mechanisms of action and target patient populations.

Stakeholder Impact

• Positive for shareholders as it represents progress in the company's drug development pipeline.
• Potentially positive for patients suffering from neuropathic pain if Ketamir-2 proves to be safe and effective.
• May have a positive impact on the company's employees and partners involved in the development and commercialization of Ketamir-2.

Next Steps

• Completion of the Phase 1 clinical trial.
• Initiation of a Phase 2a clinical trial in diabetic neuropathic pain.
• Analysis of safety, tolerability, and pharmacokinetic data from the Phase 1 trial.
• Collection and analysis of first human efficacy data in the first half of 2026.

Key Dates

Keywords

Ketamir-2, neuropathic pain, clinical trial, Phase 1, MIRA Pharmaceuticals, ketamine analog, pharmaceuticals